BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating. BofA said the update reflects changes made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.

On March 30, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced that its applications for a proposed biosimilar to Xolair, oromalizumab, have been accepted for review by both the U.S. FDA and the European Medicines Agency. The filings include a Biologics License Application and a Marketing Authorization Application and cover all approved indications of the reference product, including moderate-to-severe persistent allergic asthma.

BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42

Pixabay/Public Domain

On the same day, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval of Ponlimsi as a biosimilar to Prolia. The company said the approval covers all indications of the reference product, including treatment of postmenopausal women with osteoporosis at high risk for fracture, supported by data showing comparable efficacy, safety, and immunogenicity.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops and markets generic and biopharmaceutical medicines globally.

While we acknowledge the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.